Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:22 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma
NCT04624113 · Washington University School of Medicine · PHASE1 · terminated · last registry update 2024-02-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Ipsen bought out Epizyme” | – | Registry record, Washington University School of Medicine |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against EZH2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-10-03Results posted on the registry: Epizyme, Inc., Tazemetostat (NCT02601937)
- 2024-08-26Results posted on the registry: Epizyme, Inc., Tazemetostat + Itraconazole (NCT04537715)
- 2024-03-25Also stopped (terminated): Epizyme, Inc., Tazemetostat + Rituximab (NCT04762160)
- 2023-11-21Results posted on the registry: Epizyme, Inc., Tazemetostat + Rituximab (NCT04762160)
- 2023-09-22Also stopped (withdrawn): Edwin Posadas, MD, Tazverik (NCT05567679)
- 2023-08-15Also stopped (withdrawn): Epizyme, Inc., Tazemetostat + Tafasitamab (NCT05205252)
- 2023-08-04Results posted on the registry: Epizyme, Inc., Tazemetostat + Prednisolone (NCT01897571)
- 2023-07-07Also stopped (withdrawn): Jacob Soumerai, MD, TAZEMETOSTAT + Zandelisib (NCT05604417)
- 2023-05-31Also stopped (withdrawn): City of Hope Medical Center, Tazemetostat + Ublituximab (NCT05152459)
- 2023-05-18Also stopped (withdrawn): Dana-Farber Cancer Institute, Implantable Microdevice (IMD) (NCT05774886)
- 2023-04-27Results posted on the registry: National Cancer Institute (NCI), Tazemetostat (NCT03213665)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision